CN Patent

CN105963685B — 包含glp-1激动剂和n-(8-(2-羟基苯甲酰)氨基)辛酸盐的固体组合物

Assigned to Novo Nordisk AS · Expires 2021-01-15 · 5y expired

What this patent protects

本发明涉及包含GLP‑1激动剂和N‑(8‑(2‑羟基苯甲酰)氨基)辛酸盐的固体组合物，所述固体组合物满足了对一种优化的用于口服给药GLP‑1激动剂例如包含取代基的GLP‑1激动剂的药物组合物的需要。本发明还涉及所述固体组合物在医药中的用途。

USPTO Abstract

本发明涉及包含GLP‑1激动剂和N‑(8‑(2‑羟基苯甲酰)氨基)辛酸盐的固体组合物，所述固体组合物满足了对一种优化的用于口服给药GLP‑1激动剂例如包含取代基的GLP‑1激动剂的药物组合物的需要。本发明还涉及所述固体组合物在医药中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN105963685B
Jurisdiction
CN
Classification
—
Expires
2021-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.